ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has conditionally approved Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy in children aged 4–5. Priced at $3.2 million, Elevidys delivers a gene that produces a shortened version of the dystrophin protein missing in people with the condition. In May, an FDA advisory panel narrowly voted to recommend approval, citing patients’ urgent unmet need for treatment options—despite Elevidys’s ambiguous benefit during its sole randomized and placebo controlled clinical trial.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X